Astria Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Astria Therapeutics

07/08/2023 23:02

* Astria Therapeutics Inc  ATXS.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 49 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Astria Therapeutics Inc's reported EPS for the quarter was
a
loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Astria Therapeutics Inc shares had risen by 1.6% this
quarter and lost 43.2% so far this year.
    * The company reported a quarterly loss of $12.57 million.
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 10:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.49          -0.45          Beat
 Mar. 31 2023      -0.55          -0.40          Beat
 Dec. 31 2022      -0.71          -0.72          Missed
 Sep. 30 2022      -0.92          -0.87          Beat